Validation of serum biomarkers for detection of early- and late-stage endometrial cancer

American Journal of Obstetrics and Gynecology

Volumn 202, Issue 1, 2010, Pages 73.e1-73.e5

  Farias Eisner, Gina ^a   Su, Feng ^a   Robbins, Terry ^b   Kotlerman, Jenny ^a   Reddy, Srinivasa ^a   Farias Eisner, Robin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Pathway Diagnostics Corp   (United States)

Author keywords

biomarker; early stage; endometrial cancer; late stage

Indexed keywords

APOLIPOPROTEIN A1; CA 125 ANTIGEN; PREALBUMIN; TRANSFERRIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PAPILLARY CARCINOMA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

EID: 72149103798     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2009.07.049     Document Type: Article

References (28)

1. Endometrial cancer. In: Callahan T.L., and Caughey A.B. (Eds). Blueprints obstetrics and gynecology. 5th ed. (2008), Lippincott Williams & Wilkins, Philadelphia, PA 310-316
2. Sonoda Y., and Barakat R. Screening and the prevention of gynecologic cancer: endometrial cancer. Best Pract Res Clin Obstet Gynaecol 20 (2006) 363-377
3. Ueda S., Kapp D., Cheung M., et al. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol 198 (2008) 218.e1-218.e6
4. Jhang H., Chuang L., Visintainer P., and Ramaswamy G. CA 125 levels in the preoperative assessment of advanced-stage uterine cancer. Am J Obstet Gynecol 188 (2003) 1195-1197
5. Bast Jr. R.C., Klug T.L., St. John E., et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309 (1983) 883-887
6. Kenemans P., van Kamp G.J., Oehr P., and Verstraeten R.A. Heterologous double-determinant immunoradiometric assay CA 125 II: reliable second-generation immunoassay for determining CA 125 in serum. Clin Chem 39 (1993) 2509-2513
7. Dotters D.J. Preoperative CA 125 in endometrial cancer: is it useful?. Am J Obstet Gynecol 182 (2000) 1328-1334
8. Koper N.P., Massuger L.F., Thomas C.M., Kiemeney L.A., and Verbeek A.L. Serum CA 125 measurements to identify patients with endometrial cancer who require lymphadenectomy. Anticancer Res 18 (1998) 1897-1902
9. Lo S.S., Cheng D.K., Ng T.Y., Wong L.C., and Ngan H.Y. Prognostic significance of tumour markers in endometrial cancer. Tumour Biol 18 (1997) 241-249
10. Nossov V., Amneus M., Su F., et al. The early detection of ovarian cancer: from traditional methods to proteomics: can we really do better than serum CA-125?. Am J Obstet Gynecol 199 (2008) 215-223
11. Nossov V., Su F., Amneus M., Birrer M., Reddy S., and Farias-Eisner R. Validation of serum biomarkers for detection of early stage ovarian cancer. Am J Obstet Gynecol 200 (2009) e1-e3
12. Wulfkuhle J.D., Liotta L.A., and Petricoin E.F. Proteomic applications for the early detection of cancer. Nat Rev Cancer 3 (2003) 267
13. Zhu L.R., Zhuang W.Y., Yu L., Zheng Y.H., Zhang J.Z., and Liao Q.P. Serum proteomic features for detection of endometrial cancer. Int J Gynecol Cancer 16 (2006) 1374-1378
14. Su F., Farias-Eisner R., and Reddy S. Validation of candidate serum ovarian cancer biomarkers for early detection. Biomarkers Insights 2 (2007) 369-375
15. Kozak K.R., Amneus M.W., Pusey S.M., et al. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci U S A 100 (2003) 12343-12348
16. Kozak K.R., Su F., Whitelegge J.P., Faull K., Farias-Eisner R., and Reddy S. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 5 (2005) 4589-4596
17. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
18. Nilodd J.M., Klug R.L., Schaetzl E., Zurawski Jr. V.R., Knapp R.C., and Bast Jr. R.C. Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol 148 (1984) 1057-1058
19. Duk J.M., Aalders J.G., Fleuren G.J., and de Bruign H.W. CA 125: a useful marker in endometrial carcinoma. Am J Obstet Gynecol 155 (1986) 1097-1102
20. Cherchi P.L., Dessole S., Ruiu G.A., et al. The value of serum CA 125 and association CA 125/CA 19-9 in endometrial carcinoma. Eur J Gynaecol Oncol 20 (1999) 315-317
21. Takeshima N., Shimizu Y., Umezawa S., et al. Combined assay of serum levels of CA125 and CA19-9 in endometrial carcinoma. Gynecol Oncol 54 (1994) 321-326
22. Hareyama H., Sakuragi N., Makinoda S., and Fujimoto S. Serum and tissue measurements of CA72-4 in patients with endometrial carcinoma. J Clin Pathol 49 (1996) 967-970
23. Beck E.P., Wagner M., Anselmino L., Xu F., Bast Jr. R.C., and Jaeger W. Is OVX1 a suitable marker for endometrial cancer?. Gynecol Oncol 65 (1997) 291-296
24. Lo S.S., Khoo U.S., Cheng D.K., Ng T.Y., Wong L.C., and Ngan H.Y. Role of serial tumor markers in the surveillance for recurrence in endometrial cancer. Cancer Detect Prev 23 (1999) 397-400
25. Jacobs I.J., and Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 3 (2004) 355-366
26. Wilder J.L., Pavlik E., Straughn J.M., et al. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation. Gynecol Oncol 89 (2003) 233-235
27. Scambia G., Gadducci A., Panici P.B., et al. Combined use of CA 125 and CA 15-3 in patients with endometrial carcinoma. Gynecol Oncol 54 (1994) 292-297
28. Moore R.G., Brown A.K., Miller M.C., et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol 110 (2008) 196-201